KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.
NDSC`s solutions are widely adopted and in use across the entire healthcare provider market in all 50 states and Europe. Organizations ranging from large, multi-state, integrated delivery networks to standalone ambulatory care settings, caregivers trust NDSC CareSelect™ platform to manage and track the actionable delivery of thousands of evidence-based guidelines.
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
Rally® believes in putting health care in the hands of individuals with a seamless experience, providing personalized, data-driven information and recommendations that can help improve outcomes and decrease costs for everyone. Rallys Health Solutions help members set personalized daily goals, gives recommendations, and incentivizes progress with rewards. Rallys Care Solutions make health benefits easy to understand and care easy to find on the computer or the Rally app. More than 20 million consumers currently have access to the Rally platform through payers such as UnitedHealthcare, BlueCross BlueShield of South Carolina, and thousands of employer groups. Across offices in Washington, D.C., San Francisco, Chicago, Minneapolis, Denver, and Las Vegas, Rallyers have dedicated themselves to transforming the health care industry for the better—Together.
Camtech Inc is a New Palestine, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.